OptiBiotix Health Plc subsidiary receives USFDA letter confirming LPLDL®'s GRAS status

  • Oct 09, 2019 BST
  • Team Kalkine
  • OptiBiotix Health Plc’s (OPTI) fully-owned subsidiary ProBiotix Health Ltd has finalized the process validation under Pharmaceutical GMP (Good Manufacturing Practices) for LPLDL® as a drug substance.
  • The company has also received a letter from the USFDA (United States Food and Drug Administration) confirming LPLDL®s GRAS status (Generally Recognized As Safe status), a designation that a substance added to food is considered safe.
  • On 9th October 2019, at the time of writing, GMT 08:08 AM, OPTI shares were trading at GBX 47.00, up by 3.25 points or 7.43% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK